Pfizer Interest In Biosimilars Appears To Decline As Firm Ceases To Split Out Segment

Launch Of Humira Challenger In 2023 May Rejuvenate The Area

 
• By Chloe Kent
  
Pfizer logo next to syringe
Pfizer's biosimilar business appears to be on the backburner for the time being • Source: Shutterstock

More from Biosimilars

More from Products